---
layout: default
title: Prednisolone Acetate
description: "Prednisolone Acetate 的老藥新用潛力分析。初步證據等級 L4，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 139
evidence_level: L2
indication_count: 10
---

# Prednisolone Acetate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L4</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Prednisolone Acetate：從眼部過敏到寄生蟲性結膜炎

## 一句話總結

<p class="key-answer" data-question="Prednisolone Acetate 可以用於治療什麼新適應症？">
Prednisolone acetate 是一種眼用皮質類固醇，原本用於眼瞼炎、結膜炎、角膜炎等過敏性眼疾。TxGNN 模型預測它可能對**寄生蟲性結膜炎 (Parasitic Conjunctivitis)** 有效，目前有 **1 篇文獻**支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 眼瞼炎、結膜炎、角膜炎、鞏膜炎、虹彩毛樣體炎等過敏性疾患 |
| 預測新適應症 | 寄生蟲性結膜炎 (Parasitic Conjunctivitis) |
| TxGNN 預測分數 | 99.74% |
| 證據等級 | L4 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Proceed with Guardrails |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. parasitic conjunctivitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.74%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Prednisolone acetate 是一種局部皮質類固醇，具有強效的抗炎和免疫調節作用。它主要用於治療各種眼部過敏性和炎症性疾病，包括結膜炎、角膜炎和虹彩毛樣體炎。</p>

<p>寄生蟲性結膜炎是由寄生蟲感染引起的結膜炎症，在感染控制後，局部類固醇可用於減少持續的炎症反應。根據文獻報導，在 Dirofilaria repens（一種眼部寄生蟲病）的治療中，類固醇經常與抗生素併用來控制局部炎症反應。</p>

<p>由於原適應症（各種類型的結膜炎）與新預測適應症（寄生蟲性結膜炎）在病理機轉上有相似性——都涉及結膜的炎症反應——皮質類固醇的抗炎作用在機轉上可能適用於控制寄生蟲感染後的炎症。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr>
<th>試驗編號</th>
<th>階段</th>
<th>狀態</th>
<th>人數</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04705584">NCT04705584</a></td>
<td>N/A</td>
<td>未知</td>
<td>180</td>
<td>探討免疫抑制劑治療春季卡他性結膜炎</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01437982">NCT01437982</a></td>
<td>Phase 4</td>
<td>已完成</td>
<td>140</td>
<td>Lotemax 眼用懸浮液的安全性和療效評估</td>
</tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>年份</th>
<th>類型</th>
<th>期刊</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26846596/">26846596</a></td>
<td>2016</td>
<td>Case Report</td>
<td>Eye</td>
<td>Dirofilaria repens 眼部感染，類固醇與抗生素併用治療</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/29801089/">29801089</a></td>
<td>2018</td>
<td>Case Report</td>
<td>JAMA Ophthalmology</td>
<td>慢性濾泡性結膜炎的治療報告</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26984315/">26984315</a></td>
<td>2016</td>
<td>Review</td>
<td>Advances in Therapy</td>
<td>Loteprednol etabonate 對眼壓的影響</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. chronic follicular conjunctivitis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.74%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04705584" target="_blank">NCT04705584</a></td><td>NA</td><td>UNKNOWN</td><td>180</td><td>Role of Topical Immuonosuppressant in the Management of Spring Catarrh: a Compar...</td></tr>
</tbody>
</table>

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29801089/" target="_blank">29801089</a></td><td>2018</td><td>Article</td><td>JAMA ophthalmology</td><td>Chronic Follicular Conjunctivitis in a Middle-aged Woman.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. serous conjunctivitis except viral</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.74%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. conjunctival folliculosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.74%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. papillary conjunctivitis</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04705584" target="_blank">NCT04705584</a></td><td>NA</td><td>UNKNOWN</td><td>180</td><td>Role of Topical Immuonosuppressant in the Management of Spring Catarrh: a Compar...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01437982" target="_blank">NCT01437982</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Oph...</td></tr>
</tbody>
</table>

<h3>相關文獻（6 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26984315/" target="_blank">26984315</a></td><td>2016</td><td>Article</td><td>Advances in therapy</td><td>Impact of the Topical Ophthalmic Corticosteroid Loteprednol ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18724159/" target="_blank">18724159</a></td><td>2008</td><td>Article</td><td>Cornea</td><td>Papillary conjunctivitis associated with Kikuchi disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29260110/" target="_blank">29260110</a></td><td>2017</td><td>Article</td><td>American journal of </td><td>Surgical treatment outcome of medically refractory huge gian...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9713785/" target="_blank">9713785</a></td><td>1998</td><td>Article</td><td>Journal of glaucoma</td><td>Change in intraocular pressure during long-term use of lotep...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12917176/" target="_blank">12917176</a></td><td>2003</td><td>Article</td><td>Ophthalmology</td><td>Topical cyclosporine A 0.5% as a possible new treatment for ...</td></tr>
</tbody>
</table>
<p><em>...及其他 1 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. Angelucci syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. pseudomembranous conjunctivitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（3 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15523196/" target="_blank">15523196</a></td><td>2004</td><td>Article</td><td>Current opinion in o</td><td>Ocular manifestations of graft versus host disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32621983/" target="_blank">32621983</a></td><td>2020</td><td>Article</td><td>Journal of AAPOS : t</td><td>Ocular manifestations of mycoplasma-induced rash and mucosit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40248181/" target="_blank">40248181</a></td><td>2025</td><td>Article</td><td>Beyoglu eye journal</td><td>Ligneous Conjunctivitis with Plasminogen Deficiency Treated ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. acute hemorrhagic conjunctivitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.70%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. vernal conjunctivitis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04705584" target="_blank">NCT04705584</a></td><td>NA</td><td>UNKNOWN</td><td>180</td><td>Role of Topical Immuonosuppressant in the Management of Spring Catarrh: a Compar...</td></tr>
</tbody>
</table>

<h3>相關文獻（19 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24055903/" target="_blank">24055903</a></td><td>2013</td><td>Article</td><td>Cornea</td><td>Comparison of the effects of topical cyclosporine a 0.05%, c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12931748/" target="_blank">12931748</a></td><td>2003</td><td>Article</td><td>Asian Pacific journa</td><td>Vernal keratoconjunctivitis in Thailand.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26984315/" target="_blank">26984315</a></td><td>2016</td><td>Article</td><td>Advances in therapy</td><td>Impact of the Topical Ophthalmic Corticosteroid Loteprednol ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8977483/" target="_blank">8977483</a></td><td>1996</td><td>Article</td><td>Investigative ophtha</td><td>Topical cyclosporine inhibits mast cell-mediated conjunctivi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35692541/" target="_blank">35692541</a></td><td>2022</td><td>Article</td><td>Frontiers in medicin</td><td>Ovalbumin-Induced Allergic Inflammation Diminishes Cross-Lin...</td></tr>
</tbody>
</table>
<p><em>...及其他 14 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. postinfectious vasculitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 多張許可證 | 乙酸培尼皮質醇 | 眼用製劑 | 眼瞼炎、結膜炎、角膜炎、鞏膜炎、虹彩毛樣體炎等過敏性疾患 |

## 安全性考量

安全性資訊請參考原廠仿單。

眼用皮質類固醇的常見注意事項包括：
- 長期使用可能導致眼壓升高
- 可能增加感染風險
- 不建議用於真菌或病毒性眼部感染

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
Prednisolone acetate 作為眼用皮質類固醇，其抗炎機轉在寄生蟲感染控制後的炎症管理上具有合理的應用基礎。文獻已有支持在寄生蟲性眼部感染中併用類固醇的案例。

**若要推進需要：**
- 確認寄生蟲感染已被有效控制
- 監測眼壓變化
- 評估是否需要同時使用抗寄生蟲藥物


---

## 相關藥物報告

- [Salicylamide]({{ "/drugs/salicylamide/" | relative_url }}) - 證據等級 L4
- [Rotigotine]({{ "/drugs/rotigotine/" | relative_url }}) - 證據等級 L4
- [Nystatin]({{ "/drugs/nystatin/" | relative_url }}) - 證據等級 L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - 證據等級 L4
- [Ritonavir]({{ "/drugs/ritonavir/" | relative_url }}) - 證據等級 L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Prednisolone Acetate老藥新用驗證報告. https://twtxgnn.yao.care/drugs/prednisolone_acetate/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_prednisolone_acetate,
  title = {Prednisolone Acetate老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisolone_acetate/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
